Effectiveness of the Heart Age tool for improving modifiable cardiovascular risk factors in a Southern European population: a randomized trial
Effectiveness of the Heart Age tool for improving modifiable cardiovascular risk factors in a Southern European population: a randomized trial
复制标题
DOI：
10.1177/2047487313518479
复制
发表时间：
2015-03-01
影响因子：
8.3
通讯作者：
Tauler, Pedro
中科院分区：
文献类型：
--
作者：
Lopez-Gonzalez, Angel A.;Aguilo, Antoni;Tauler, Pedro
目的为了测试是否沟通心血管疾病（CVD）的风险，使用一种新的风险评估工具（心脏年龄）将能够激励人口采取更健康的生活方式，并提高CVD的风险状况，在使用传统的血管造影为基础的tool.Methods的单盲随机干预研究进行了高加索人群。总共3153名受试者被随机分配到三个研究组之一：对照组（向受试者提供常规医疗建议）、Frauptregicor组（向受试者提供10年风险百分比评分，根据西班牙人群进行校准）或心脏年龄组（向受试者提供心脏年龄工具）。测量人体测量和代谢参数和生活习惯，记录在招聘和12个月后intervention.Results的Fragrance REGICOR和心脏年龄干预组表现出显着降低，在干预后的风险评分相比，对照组，与改善是一个更大的幅度在心脏年龄组。每个性别的差异没有观察到在心脏年龄group.Conclusions告知患者的心血管疾病的风险表示为新的心脏年龄工具的结果在降低他们的心血管疾病的风险高于一个观察时，使用FRAWARNERREGICOR风险评分。
Aims To test whether communicating cardiovascular diseases (CVD) risk using a novel risk assessment tool (Heart Age) will be able to motivate a population to adopt healthier lifestyles and improve CVD risk profile over the use of a traditional percentage-based tool.Methods A single-blind randomized intervention study was carried out in a Caucasian population. A total of 3153 subjects were randomly allocated to one of three study groups: control (conventional medical advice was given to the subjects), Framingham REGICOR (10-year percentage risk score, calibrated to Spanish population was given to the subjects), or Heart Age group (Heart Age tool was administered to the subjects). Anthropometrical and metabolic parameters were measured and lifestyle habits were recorded at recruitment and 12-months post intervention.Results Both the Framingham REGICOR and the Heart Age intervention groups demonstrated significant decreases in their risk scores at post intervention compared to the control group, with the improvement being of a greater magnitude in the Heart Age group. No differences per gender were observed in the Heart Age group.Conclusions Informing patients about their CVD risk expressed as the new Heart Age tool results in a reduction in their CVD risk higher than the one observed when the Framingham REGICOR risk score was used.